54118-76-2

Basic information

• Product Name: 3-BROMO-4''-METHOXYBENZOPHENONE
• Synonyms: (3-Bromophenyl)(4-methoxyphenyl)methanone, 4-(3-Bromobenzoyl)anisole
• CAS NO: 54118-76-2
• Molecular Formula: C₁₄H₁₁BrO₂
• Molecular Weight: 291.143
• Mol File: 54118-76-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 191°C
• Boiling Point: 401.6 °C at 760 mmHg
• Flash Point: 196.7 °C
• Appearance: /
• Density: 1.401 g/cm³
• Vapor Pressure: 1.16E-06mmHg at 25°C
• Refractive Index: 1.593
• CAS DataBase Reference: 3-BROMO-4''-METHOXYBENZOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4''-METHOXYBENZOPHENONE(54118-76-2)
• EPA Substance Registry System: 3-BROMO-4''-METHOXYBENZOPHENONE(54118-76-2)

Safety Data

• Hazardous Substances Data: 54118-76-2(Hazardous Substances Data)

Usage

General Description

3-Bromo-4’-methoxybenzophenone is a chemical compound with the formula C14H11BrO2. It is a benzophenone derivative that contains a bromine and a methoxy group. 3-BROMO-4''-METHOXYBENZOPHENONE is commonly used as a photoinitiator in the production of various polymer materials, such as UV-curable coatings, inks, adhesives, and dental materials. It absorbs ultraviolet light and then initiates a photopolymerization process which helps to create a durable and cross-linked polymer network. Additionally, 3-Bromo-4’-methoxybenzophenone can also be used as an intermediate in the production of pharmaceuticals and other organic compounds due to its ability to undergo various chemical reactions. However, it is important to handle this compound with care as it should be stored in a cool, dry place and protected from direct sunlight.

InChI:InChI=1/C14H11BrO2/c1-17-13-7-5-10(6-8-13)14(16)11-3-2-4-12(15)9-11/h2-9H,1H3

Upstream product

• 1711-09-7 3-bromobenzoyl chloride 
• 100-66-3 methoxybenzene 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 2042-37-7 o-cyanobromobenzene 
• 6462-50-6 sodium 4-methoxybenzenesulfinate 
• 585-76-2 m-bromobenzoic acid 

Downstream Products

• 114740-34-0 1-(3-bromo-phenyl)-1,2-bis-(4-methoxy-phenyl)-ethene 
• 1428526-48-0 C₁₅H₁₄BrNO₂ 
• 960388-60-7 (3-bromophenyl)(4-methoxyphenyl)methylamine 
• 1428526-50-4 C₁₉H₂₂BrNO₃ 
• 1428526-51-5 C₂₃H₃₂NO₆P 
• 1428526-52-6 diethyl 3-((4-hydroxy-2-(pyridin-2-yl)pyrimidine-5-carboxamido)(4-methoxyphenyl)methyl)phenylphosphonate 
• 1428526-53-7 3-((4-hydroxy-2-(pyridin-2-yl)pyrimidine-5-carboxamido)(4-methoxyphenyl)methyl)phenylphosphonic acid 
• 53039-49-9 1-bromo-3-(4-methoxylbenzyl)benzene 
• 1436713-00-6 3-methoxy-5-(4-methoxyphenyl)-5-(3-(pyridin-3-yl)phenyl)pyrrolidin-2-one 
• 1436712-97-8 5-(3-bromophenyl)-3-methoxy-5-(4-methoxyphenyl)pyrrolidin-2-one 
• 1436712-94-5 5-(3-bromophenyl)-3-hydroxy-5-(4-methoxyphenyl)pyrrolidin-2-one 
• 1436712-91-2 C₁₈H₁₈BrNO₄ 
• 1436712-88-7 C₂₀H₂₂BrNO₄S 
• 1436712-82-1 (3-bromophenyl)(4-methoxyphenyl)methanone oxime 

Relevant articles and documents

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

Palladium(II)-catalyzed desulfitative synthesis of aryl ketones from sodium arylsulfinates and nitriles: Scope, limitations, and mechanistic studies

A fast and efficient protocol for the palladium(II)-catalyzed production of aryl ketones from sodium arylsulfinates and various organic nitriles under controlled microwave irradiation has been developed. The wide scope of the reaction has been demonstrated by combining 14 sodium arylsulfinates and 21 nitriles to give 55 examples of aryl ketones. One additional example illustrated that, through the choice of the nitrile reactant, benzofurans are also accessible. The reaction mechanism was investigated by electrospray ionization mass spectrometry and DFT calculations. The desulfitative synthesis of aryl ketones from nitriles was also compared to the corresponding transformation starting from benzoic acids. Comparison of the energy profiles indicates that the free energy requirement for decarboxylation of 2,6-dimethoxybenzoic acid and especially benzoic acid is higher than the corresponding desulfitative process for generating the key aryl palladium intermediate. The palladium(II) intermediates detected by ESI-MS and the DFT calculations provide a detailed understanding of the catalytic cycle. (Figure Presented).

SUBSTITUTED PYRIMIDINES

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.